Zobrazeno 1 - 10
of 155
pro vyhledávání: '"Linda S. Steelman"'
Autor:
James A. McCubrey, Li V. Yang, Stephen L. Abrams, Linda S. Steelman, Matilde Y. Follo, Lucio Cocco, Stefano Ratti, Alberto M. Martelli, Giuseppa Augello, Melchiorre Cervello
Publikováno v:
Cells, Vol 11, Iss 14, p 2155 (2022)
Approximately 90% of pancreatic cancers are pancreatic ductal adenocarcinomas (PDAC). PDAC is the fourth leading cause of cancer death world-wide. Therapies for PDAC are largely ineffective due to the dense desmoplastic tumor microenvironment which p
Externí odkaz:
https://doaj.org/article/4331f5d461c746a0aacfcd0c54461ebf
Autor:
James Andrew McCubrey, Stephen L. Abrams, Linda S. Steelman, Lucio Cocco, Stefano Ratti, Alberto M. Martelli, Paolo Lombardi, Agnieszka Gizak, Przemysław Duda
Publikováno v:
Biomolecules, Vol 12, Iss 2, p 276 (2022)
Pancreatic ductal adenocarcinoma (PDAC) is the most common form of pancreatic cancer. In ~75% of PDAC, the tumor suppressor TP53 gene is mutated. Novel approaches to treat cancer involve compounds called mutant TP53 reactivators. They interact with m
Externí odkaz:
https://doaj.org/article/aac6b390233f4ba7924495fb91e906e6
Autor:
Stephen L. Abrams, Przemysław Duda, Shaw M. Akula, Linda S. Steelman, Matilde L. Follo, Lucio Cocco, Stefano Ratti, Alberto M. Martelli, Giuseppe Montalto, Maria Rita Emma, Melchiorre Cervello, Dariusz Rakus, Agnieszka Gizak, James A. McCubrey
Publikováno v:
Cells, Vol 11, Iss 5, p 794 (2022)
The TP53 tumor suppressor is mutated in ~75% of pancreatic cancers. The mutant TP53 protein in pancreatic ductal adenocarcinomas (PDAC) promotes tumor growth and metastasis. Attempts have been made to develop molecules that restore at least some of t
Externí odkaz:
https://doaj.org/article/b88503daf256434e9d204e634e50ec26
Autor:
Stephen L. Abrams, Shaw M. Akula, Akshaya K. Meher, Linda S. Steelman, Agnieszka Gizak, Przemysław Duda, Dariusz Rakus, Alberto M. Martelli, Stefano Ratti, Lucio Cocco, Giuseppe Montalto, Melchiorre Cervello, Peter Ruvolo, Massimo Libra, Luca Falzone, Saverio Candido, James A. McCubrey
Publikováno v:
Cells, Vol 10, Iss 4, p 816 (2021)
Glycogen synthase kinase-3 (GSK-3) is a regulator of signaling pathways. KRas is frequently mutated in pancreatic cancers. The growth of certain pancreatic cancers is KRas-dependent and can be suppressed by GSK-3 inhibitors, documenting a link betwee
Externí odkaz:
https://doaj.org/article/40c21af23bd74ea8a11c56b197a2955e
Autor:
Przemysław Duda, Shaw M. Akula, Stephen L. Abrams, Linda S. Steelman, Alberto M. Martelli, Lucio Cocco, Stefano Ratti, Saverio Candido, Massimo Libra, Giuseppe Montalto, Melchiorre Cervello, Agnieszka Gizak, Dariusz Rakus, James A. McCubrey
Publikováno v:
Cells, Vol 9, Iss 5, p 1110 (2020)
Glycogen synthase kinase 3 (GSK-3) is a serine/threonine (S/T) protein kinase. Although GSK-3 originally was identified to have functions in regulation of glycogen synthase, it was subsequently determined to have roles in multiple normal biochemical
Externí odkaz:
https://doaj.org/article/4013e82b8ba443de968a8ae058a04c3d
Autor:
James A. McCubrey, Akshaya K. Meher, Shaw M. Akula, Stephen L. Abrams, Linda S. Steelman, Michelle M. LaHair, Richard A. Franklin, Alberto M. Martelli, Stefano Ratti, Lucio Cocco, Fulvio Barbaro, Przemysław Duda, Agnieszka Gizak
Publikováno v:
Aging. 14:3365-3386
TP53 is a master regulator of many signaling and apoptotic pathways involved in: aging, cell cycle progression, gene regulation, growth, apoptosis, cellular senescence, DNA repair, drug resistance, malignant transformation, metastasis, and metabolism
Autor:
Alessandro Gulino, Linda S. Steelman, Maria Rita Emma, Lydia Giannitrapani, Giuseppa Augello, Antonella Cusimano, James A. McCubrey, Melchiorre Cervello, Maurizio Soresi, Beatrice Belmonte, Giuseppe Montalto, Shaw M. Akula, Stephen L. Abrams
Publikováno v:
Aging (Albany NY)
Aging (Albany, N.Y. Online) (2020): 3054–3094. doi:10.18632/aging.102777
info:cnr-pdr/source/autori:Cervello M; Emma MR; Augello G; Cusimano A; Giannitrapani L; Soresi M; Akula SM; Abrams SL; Steelman LS; Gulino A; Belmonte B; Montalto G; McCubrey JA;/titolo:New landscapes and horizons in hepatocellular carcinoma therapy./doi:10.18632%2Faging.102777/rivista:Aging (Albany, N.Y. Online)/anno:2020/pagina_da:3054/pagina_a:3094/intervallo_pagine:3054–3094/volume
Aging (Albany, N.Y. Online) (2020): 3054–3094. doi:10.18632/aging.102777
info:cnr-pdr/source/autori:Cervello M; Emma MR; Augello G; Cusimano A; Giannitrapani L; Soresi M; Akula SM; Abrams SL; Steelman LS; Gulino A; Belmonte B; Montalto G; McCubrey JA;/titolo:New landscapes and horizons in hepatocellular carcinoma therapy./doi:10.18632%2Faging.102777/rivista:Aging (Albany, N.Y. Online)/anno:2020/pagina_da:3054/pagina_a:3094/intervallo_pagine:3054–3094/volume
Hepatocellular carcinoma (HCC), is the sixth most frequent form of cancer and leads to the fourth highest number of deaths each year. HCC results from a combination of environmental factors and aging as there are driver mutations at oncogenes which o
Autor:
Lucio Cocco, Linda S. Steelman, Giuseppe Montalto, Shaw M. Akula, Stephen L. Abrams, James A. McCubrey, Saverio Candido, Alberto M. Martelli, Agnieszka Gizak, Stefano Ratti, Dariusz Rakus, Massimo Libra, Melchiorre Cervello
Publikováno v:
Advances in Biological Regulation
79 (2021). doi:10.1016/j.jbior.2020.100780
info:cnr-pdr/source/autori:Abrams SL; Akula SM; Martelli AM; Cocco L; Ratti S; Libra M; Candido S; Montalto G; Cervello M; Gizak A; Rakus D; Steelman LS; McCubrey JA;/titolo:Sensitivity of pancreatic cancer cells to chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals can be regulated by WT-TP53/doi:10.1016%2Fj.jbior.2020.100780/rivista:Advances in Biological Regulation (Print)/anno:2021/pagina_da:/pagina_a:/intervallo_pagine:/volume:79
79 (2021). doi:10.1016/j.jbior.2020.100780
info:cnr-pdr/source/autori:Abrams SL; Akula SM; Martelli AM; Cocco L; Ratti S; Libra M; Candido S; Montalto G; Cervello M; Gizak A; Rakus D; Steelman LS; McCubrey JA;/titolo:Sensitivity of pancreatic cancer cells to chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals can be regulated by WT-TP53/doi:10.1016%2Fj.jbior.2020.100780/rivista:Advances in Biological Regulation (Print)/anno:2021/pagina_da:/pagina_a:/intervallo_pagine:/volume:79
Pancreatic ductal adenocarcinoma (PDAC) is a highly metastatic malignancy. Approximately 85% of pancreatic cancers are classified as PDACs. The survival of PDAC patients is very poor and only 5–10% of patients survive 5 years after diagnosis. Mutat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f4dc94b168075da14e21c4cde71eb4b
http://hdl.handle.net/11585/855470
http://hdl.handle.net/11585/855470
Autor:
Lucio Cocco, Przemysław Duda, Peter P. Ruvolo, Massimo Libra, Giuseppe Montalto, Agnieszka Gizak, Stefano Ratti, Melchiorre Cervello, Shaw M. Akula, Linda S. Steelman, Dariusz Rakus, Stephen L. Abrams, Alberto M. Martelli, Akshaya K. Meher, Saverio Candido, James A. McCubrey, Luca Falzone
Publikováno v:
Cells 10 (2021). doi:10.3390/cells10040816
info:cnr-pdr/source/autori:Stephen L Abrams; Shaw M Akula; Akshaya K Meher; Linda S Steelman; Agnieszka Gizak; Przemys?aw Duda; Dariusz Rakus; Alberto M Martelli; Stefano Ratti; Lucio Cocco; Giuseppe Montalto; Melchiorre Cervello; Peter Ruvolo; Massimo Libra; Luca Falzone; Saverio Candido; James A McCubrey/titolo:GSK-3? Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals/doi:10.3390%2Fcells10040816/rivista:Cells/anno:2021/pagina_da:/pagina_a:/intervallo_pagine:/volume:10
Cells
Volume 10
Issue 4
Cells, Vol 10, Iss 816, p 816 (2021)
info:cnr-pdr/source/autori:Stephen L Abrams; Shaw M Akula; Akshaya K Meher; Linda S Steelman; Agnieszka Gizak; Przemys?aw Duda; Dariusz Rakus; Alberto M Martelli; Stefano Ratti; Lucio Cocco; Giuseppe Montalto; Melchiorre Cervello; Peter Ruvolo; Massimo Libra; Luca Falzone; Saverio Candido; James A McCubrey/titolo:GSK-3? Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals/doi:10.3390%2Fcells10040816/rivista:Cells/anno:2021/pagina_da:/pagina_a:/intervallo_pagine:/volume:10
Cells
Volume 10
Issue 4
Cells, Vol 10, Iss 816, p 816 (2021)
Glycogen synthase kinase-3 (GSK-3) is a regulator of signaling pathways. KRas is frequently mutated in pancreatic cancers. The growth of certain pancreatic cancers is KRas-dependent and can be suppressed by GSK-3 inhibitors, documenting a link betwee
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9bc9ebd9624ff356255eb057b042a79
http://www.scopus.com/record/display.url?eid=2-s2.0-85105067732&origin=inward
http://www.scopus.com/record/display.url?eid=2-s2.0-85105067732&origin=inward
Autor:
Paolo Lombardi, Giuseppe Montalto, Lucio Cocco, Massimo Libra, Matilde L. Follo, James A. McCubrey, Shaw M. Akula, Stephen L. Abrams, Luca Falzone, Linda S. Steelman, Melchiorre Cervello, Saverio Candido, Stefano Ratti, Alberto M. Martelli
Publikováno v:
Advances in Biological Regulation
83 (2022). doi:10.1016/j.jbior.2021.100840
info:cnr-pdr/source/autori:Abrams S.L.; Akula S.M.; Steelman L.S.; Follo M.L.; Cocco L.; Ratti S.; Martelli A.M.; Libra M.; Falzone L.; Candido S.; Montalto G.; Cervello M.; Lombardi P.; McCubrey J.A./titolo:Effects of the MDM2 inhibitor Nutlin-3a on sensitivity of pancreatic cancer cells to berberine and modified berberines in the presence and absence of WT-TP53/doi:10.1016%2Fj.jbior.2021.100840/rivista:Advances in Biological Regulation (Print)/anno:2022/pagina_da:/pagina_a:/intervallo_pagine:/volume:83
83 (2022). doi:10.1016/j.jbior.2021.100840
info:cnr-pdr/source/autori:Abrams S.L.; Akula S.M.; Steelman L.S.; Follo M.L.; Cocco L.; Ratti S.; Martelli A.M.; Libra M.; Falzone L.; Candido S.; Montalto G.; Cervello M.; Lombardi P.; McCubrey J.A./titolo:Effects of the MDM2 inhibitor Nutlin-3a on sensitivity of pancreatic cancer cells to berberine and modified berberines in the presence and absence of WT-TP53/doi:10.1016%2Fj.jbior.2021.100840/rivista:Advances in Biological Regulation (Print)/anno:2022/pagina_da:/pagina_a:/intervallo_pagine:/volume:83
Approaches to improve pancreatic cancer therapy are essential as this disease has a very bleak outcome. Approximately 80% of pancreatic cancers are pancreatic ductal adenocarcinomas (PDAC). A key regulatory gene frequently mutated (∼75%) in PDAC is